The PDF file includes: Fig. S1 . HbS fiber nucleation and growth occur throughout the sample. Fig. S2 . MSD analysis confirms variance analysis. Table S1 . Exact values from ANOVA statistical tests. Legends for movies S1 and S2 Reference (39)
Supplementary Discussion

Other Supplementary Material for this manuscript includes the following:
(available at advances.sciencemag.org/cgi/content/full/5/3/eaau1086/DC1) Movie S1 (.mov format). HbS fiber assembly. Movie S2 (.mov format). Bundle of HbS fibers grown along the same trajectory.
Supplementary Discussion:
Comparing to previous estimates of HbS kinetic rate constants
The most well cited estimates of the on-rate constant from bulk HbS fiber assembly come from a three-part series discussing the double nucleation model and the associated bulk assembly kinetics (21, 22, 39) . In the second paper in this series, Ferrone , Hofrichter, and Eaton (21) estimated an on-rate constant from bulk HbS fiber assembly (2 µM 
HbS fiber growth efficiency
Using our values for the kinetic rates (k on and k off ) and observed growth rates, then under physiological conditions (5 mM at 37°C) we estimate there would be on the order of 780,000
(k on γC = 4600 mM -1 s -1 x 34 x 5 = 782,000) addition events per second and 750,000 loss events per second for a net-addition of 30,000 hemoglobin subunits (net rate of v g = 13.6 μm/s). This results in an addition fraction of 30,000/780,000 = 0.038, or 3.8% efficiency. Comparatively, using an average of previous single HbS fiber estimates of kinetic rate constants there would be on the order of 24,000 addition events per second (k on γC = 140 mM -1 s -1 x 34 x 5 = 23,800) and 1000 loss events per second for a net of 23,000 hemoglobin subunits (net rate of v g = 10.5 μm/s). This results in an addition fraction of 23,000/24,000 = 0.96, or 96% efficiency. These are significantly different pictures of the single fiber assembly process. In one case (using previous estimates), the vast majority of subunits that bind to the fiber end are stably incorporated (i.e.
"slow and efficient"). In the other case (using our estimates), the majority of subunits that bind to the fiber end are quickly lost, and it takes many events to stably incorporate a single subunit (i.e.
"rapid and inefficient").
Drug saturation required to inhibit growth
Let us assume there exists a drug that modestly influences the intermolecular bond free energy by +2 k B T (1.2 kcal/mol), and that the effect reduces the on-rate, possibly through steric hindrance at the HbS binding interface. To shift the growth process in favor of disassembly, the number of addition events must be less than the number of loss events, such that the net rate is negative. In the context of our estimates here, to reduce the number of addition events to 748,200 (net rate = -2,200 subunits/s = -1 μm/s), the average on-rate constant at the fiber end would only have to be reduced from 4600 mM ), and p 2 is the fraction of hemoglobin with the drug bound. Solving eq. S1 for p 2 we get
Using the numbers above, then p 2 = 0.05, thus only 5% of hemoglobin needs to be bound with the drug to shift the reaction in favor of disassembly. Thus, in the context of our updated on-rate constant estimates, it is feasible to perturb fiber growth using a drug at sub-saturating conditions, at only a fraction of the total hemoglobin concentration. The same effect would be impossible when using previous estimates of the on-rate constant, even under complete saturation, since the effect is too weak. A stronger drug effect (> +3.2 k B T = 1.9 kcal/mol) could shift the reaction in favor of disassembly, but would still require nearly complete saturation with the drug (>96%). Thus, in the context of previous on-rate estimates, one would conclude that large amounts of the drug are required to perturb assembly, as has previously been the conclusion (15, 33, 35) .
Dosage calculations to target sickle hemoglobin intermolecular bonds
For our example drug, our updated on-rate estimate means that shifting the reaction in favor of disassembly would require only 5% of hemoglobin to be bound with the drug. To determine the required dosage for such a drug, we used similar assumptions as the calculation performed in (35). Assuming a 25% hematocrit and 5 mM total hemoglobin concentration, then the total hemoglobin concentration in the blood volume is 1.25 mM. Thus a total of 62.5 µM of the drug (bound and unbound) is needed in the blood to bind to 5% of the hemoglobin. For a small molecule inhibitor that has a molecular weight of 300 g/mol (the chemotherapeutics paclitaxel, vinblastine, and colchicine are 854, 810, and 400 g/mol, respectively, while hydroxyurea, used in treating sickle cell disease, is 76 g/mol) and total blood volume of 4 L, there will be a total of 75 mg of drug at 62.5 µM total concentration. For an average adult with a surface area of 2 m . Hydroxyurea, is currently administered at 10 mg/kg to treat sickle cell disease, which converts to ~1800 mg/m 2 for an average adult. Therefore, the dosage of our example drug necessary to perturb HbS fiber growth is within a reasonable range of clinically relevant treatments for cancer and sickle cell disease. 
